Haemophilus Vaccines (Vaccine, Haemophilus)

Subscribe to Selected New Research on Haemophilus Vaccines

24 relevant articles (1 outcomes, 2 trials/studies) found for this Bio-Agent

Description: Vaccines or candidate vaccines containing antigenic polysaccharides from Haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine.

Also Known As:

Vaccine, Haemophilus; Haemophilus Vaccine; Hemophilus Vaccines; Vaccines, Haemophilus; Vaccines, Haemophilus influenzae; Vaccines, Hemophilus; Haemophilus influenzae Vaccines

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 314

Biological Products

Vaccines: 15360

Bacterial Vaccines: 332

Haemophilus Vaccines: 24

Haemophilus influenzae type b polysaccharide vaccine: 144

Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate: 105

Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate: 46

diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine: 11

diphtheria-tetanus-acellular pertussis-Hib-hepatitis B vaccine: 9

bacterial polysaccharide immune globulin: 8

Haemophilus influenzae HibTITER protein: 8

COMVAX: 7

D 53: 6

Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine: 6

Haemophilus influenzae type-b polysaccharide-pertussis vaccine: 1

Tetracel: 1

DtwP-HepB-Hib vaccine

Haemophilus P6 outer membrane protein

Hib-MenCY-TT vaccine

Related Diseases

1.	Infection 01/01/1999 - "Immunization with the conjugate Haemophilus vaccines has largely controlled infections caused by this pathogen. " 07/01/1994 - "Immunity to Haemophilus influenzae type b polysaccharide capsule in children with human immunodeficiency virus infection immunized with a single dose of Haemophilus vaccine." 01/01/1991 - "Immunization with Haemophilus vaccine is undertaken to prevent invasive infections due to Haemophilus influenzae type b. " 05/01/1986 - "Infection after Haemophilus vaccine." 01/01/1999 - "To date, no convincing evidence exists for the efficacy of pneumococcal polysaccharide vaccines in children with SCD, but preliminary data with the conjugate pneumococcal vaccines in normal children and those with SCD suggest that they may be as successful as Haemophilus vaccines in controlling this infection once they are available. " Order ALL the reference details at left...
2.	Whooping Cough (Pertussis) 11/01/2001 - "However, the rate of increase has slowed in recent years and HepB3 coverage remains lower than coverage attained with three doses of diphtheria-tetanus-pertussis and Haemophilus influenzae vaccines. " 11/01/1998 - "Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age." 12/15/2003 - "In this study, autoimmune diabetes-prone non-obese diabetic (NOD) mice were treated with two multivalent diphtheria, tetanus, pertussis, poliomyelitis and haemophilus vaccines (diphtheria, tetanus, acellular pertussis, inactivated polio (DTaP-IVP) or DTaP-IVP/Haemophilus influenza type b (Hib)) intraperitoneally at each of 10, 12 and 14 weeks of age. " 09/01/2009 - "In late 2008, the Wisconsin Immunization Program assessed all children at 24 months of age for completeness of the 4:3:1:3:3:1 (diphtheria, tetanus, pertussis/poliovirus/measles-containing vaccine/Haemophilus influenzae type b/hepatitis B/varicella) series by county for each of four CYs, using the WIR. " 11/01/2007 - "METHODS: Data from the 2004 National Immunization Survey were used in a series of simulations analyzing UTD coverage of the 4:3:1:3:3:1 (diphtheria, tetanus, pertussis/poliovirus/measles-containing vaccine/Haemophilus influenzae type b/hepatitis B/varicella) and 4:3:1:3:3:1 (+) pneumococcal conjugate vaccine (PCV) series. " Order ALL the reference details at left...
3.	Tetanus 11/01/2001 - "However, the rate of increase has slowed in recent years and HepB3 coverage remains lower than coverage attained with three doses of diphtheria-tetanus-pertussis and Haemophilus influenzae vaccines. " 11/01/1998 - "Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age." 12/15/2003 - "In this study, autoimmune diabetes-prone non-obese diabetic (NOD) mice were treated with two multivalent diphtheria, tetanus, pertussis, poliomyelitis and haemophilus vaccines (diphtheria, tetanus, acellular pertussis, inactivated polio (DTaP-IVP) or DTaP-IVP/Haemophilus influenza type b (Hib)) intraperitoneally at each of 10, 12 and 14 weeks of age. " 09/01/2009 - "In late 2008, the Wisconsin Immunization Program assessed all children at 24 months of age for completeness of the 4:3:1:3:3:1 (diphtheria, tetanus, pertussis/poliovirus/measles-containing vaccine/Haemophilus influenzae type b/hepatitis B/varicella) series by county for each of four CYs, using the WIR. " 11/01/2007 - "METHODS: Data from the 2004 National Immunization Survey were used in a series of simulations analyzing UTD coverage of the 4:3:1:3:3:1 (diphtheria, tetanus, pertussis/poliovirus/measles-containing vaccine/Haemophilus influenzae type b/hepatitis B/varicella) and 4:3:1:3:3:1 (+) pneumococcal conjugate vaccine (PCV) series. " Order ALL the reference details at left...
4.	Diphtheria 11/01/2001 - "However, the rate of increase has slowed in recent years and HepB3 coverage remains lower than coverage attained with three doses of diphtheria-tetanus-pertussis and Haemophilus influenzae vaccines. " 11/01/1998 - "Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age." 12/15/2003 - "In this study, autoimmune diabetes-prone non-obese diabetic (NOD) mice were treated with two multivalent diphtheria, tetanus, pertussis, poliomyelitis and haemophilus vaccines (diphtheria, tetanus, acellular pertussis, inactivated polio (DTaP-IVP) or DTaP-IVP/Haemophilus influenza type b (Hib)) intraperitoneally at each of 10, 12 and 14 weeks of age. " 09/01/2009 - "In late 2008, the Wisconsin Immunization Program assessed all children at 24 months of age for completeness of the 4:3:1:3:3:1 (diphtheria, tetanus, pertussis/poliovirus/measles-containing vaccine/Haemophilus influenzae type b/hepatitis B/varicella) series by county for each of four CYs, using the WIR. " 11/01/2007 - "METHODS: Data from the 2004 National Immunization Survey were used in a series of simulations analyzing UTD coverage of the 4:3:1:3:3:1 (diphtheria, tetanus, pertussis/poliovirus/measles-containing vaccine/Haemophilus influenzae type b/hepatitis B/varicella) and 4:3:1:3:3:1 (+) pneumococcal conjugate vaccine (PCV) series. " Order ALL the reference details at left...
5.	Poliomyelitis (Polio) 11/01/1998 - "Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age." 12/15/2003 - "In this study, autoimmune diabetes-prone non-obese diabetic (NOD) mice were treated with two multivalent diphtheria, tetanus, pertussis, poliomyelitis and haemophilus vaccines (diphtheria, tetanus, acellular pertussis, inactivated polio (DTaP-IVP) or DTaP-IVP/Haemophilus influenza type b (Hib)) intraperitoneally at each of 10, 12 and 14 weeks of age. " 10/23/2007 - "METHODS: In an open label, randomized, parallel group study, the liquid HV vaccine (HEXAVAC) (diphtheria, tetanus, 2-component acellular pertussis, inactivated poliomyelitis vaccine, Haemophilus influenzae type b conjugated to tetanus protein and hepatitis B) was administered at 2, 4, 6, and 12 months of age to all children. " 03/22/2007 - "Furthermore, co-administration of the combination vaccine with a combined diphtheria/tetanus/acellular pertussis/inactivated poliomyelitis vaccine/Haemophilus influenzae type b-TT conjugate (DTaP/IPV-Hib) vaccine to New Zealand white rabbits at a different injection site did not affect the anti-pneumococcal polysaccharide and anti-PorA antibody titres. " 07/01/2007 - "OBJECTIVE: The safety, immunogenicity and lot consistency of a fully liquid, five-component acellular pertussis combination vaccine, comprised of diphteria, tetanus and acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b (DTaP-IPV-Hib [Pediacel, sanofi pasteur, Canada]) were assessed and compared with that of Hib vaccine reconstituted with the five-component acellular pertussis combination vaccine (DTaP-IPV//Hib, Pentacel [sanofi pasteur, Canada]). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)
2.	Vaccines
3.	Hexavac
4.	Haemophilus influenzae type b polysaccharide vaccine (HIB-vaccine)
5.	Diphtheria-Tetanus-acellular Pertussis Vaccines (Tripedia)
6.	Diphtheria-Tetanus Vaccine
7.	Rubella Vaccine
8.	Pertussis Vaccine
9.	Membrane Proteins (Integral Membrane Proteins)
10.	Immunoglobulins (Immunoglobulin)

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 14726 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>